Kintara Therapeutics and TuHURA Biosciences have entered into an Exclusivity and Right of First Offer Agreement with Kineta for the potential acquisition of Kineta's KVA12123 anti-VISTA antibody and related rights and assets.
AI Assistant
TUHURA BIOSCIENCES INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.